Business ❯ Pharmaceuticals ❯ Drug Development

Weight Loss Drugs

Novo Nordisk Wegovy Eli Lilly GLP-1 Drugs AbbVie Licensing Roche Amycretin Danuglipron Ozempic Market Demand GLP-1 Agonists MariTide Tirzepatide Pfizer Zepbound GLP-1 Treatments

Lilly's Rally Deepens as U.S. Access Deal Recasts Outlook for GLP‑1 Drugs

A U.S. access deal with capped Medicare costs shifts attention to approvals that would open coverage in 2026.

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Lilly Taps Walmart for First Retail Pickup of Discounted Zepbound Vials Starting Mid-November